Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Adaptive pathways should be 'exception rather than rule'

This article was originally published in SRA

Executive Summary

Make adaptive pathways for medicines evaluation the exception rather than the rule and focus instead on therapeutic advance. A number of health groups have joined forces to send precisely that message to the European Medicines Agency.